Posted by Michael Wonder on 24 Apr 2017
Sanofi receives FDA approval of Thymoglobulin for the prevention of acute kidney transplant rejection
24 April 2017 - New U.S. indication approved for Thymoglobulin [anti-thymocyte globulin (rabbit)]; first since 1998.
Sanofi today announced that the U.S. FDA approved thymoglobulin [anti-thymocyte globulin (rabbit)], for use in conjunction with concomitant immunosuppression in the prophylaxis, or prevention, of acute rejection in patients receiving a kidney transplant.
